GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
A

Alzex Neuropharma TRRI · USD

Materials · US listing · 🇺🇸 United States

Compare

0.00

—

Close of 5 Nov 2026, in USD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

At a glance

Figures in USD, from our data supplier.

FY2022

Net income

−$165,695

FY2020FY2022

Free cash flow

−$88,200

FY2020FY2022

Shareholders' equity

−$218,083

FY2020FY2022

Income statement

Fiscal years

FY2022FY2021FY2020
Operating income−$163,490−$23,210−$3,000
Net income−$165,695$21,980−$3,000
Diluted earnings per share-0.110.01-0.00

Balance sheet

At each fiscal year end

FY2022FY2021FY2020
Total assets$19,617$219$39
Cash and short-term investments$1,020$219$39
Total liabilities$237,700$52,907$74,707
Debt$91,202—$45,190
Shareholders' equity−$218,083−$52,688−$74,668
Shares outstanding2m2m2m

Cash flow

Fiscal years

FY2022FY2021FY2020
Cash from operations−$88,199$45,370—
Capital spending−$1——
Free cash flow−$88,200$45,370—

Latest quarters

By quarter end

Jun 2024Sept 2023Jun 2023Mar 2023Dec 2022Sept 2022Jun 2022Mar 2022
Operating income−$83,676−$41,510−$41,630−$80,030−$43,000−$52,640−$34,900−$34,030
Net income−$85,579−$43,325−$43,419−$81,801−$43,000−$54,120−$34,904−$34,029
Diluted earnings per share-0.06-0.03-0.03-0.05-0.03-0.04-0.02-0.02
Total assets$7,840$6,220$7,595$8,970$19,617$19,617$1,897$189
Cash and short-term investments$160$40$40$40$1,020$1,020$1,897$189
Debt$117,124$99,285$97,472$95,679$91,202$91,202$61,717—
Shareholders' equity−$559,603−$386,728−$343,303−$299,884−$218,083−$173,583−$122,338−$86,717

Growth per year

Compound annual rate

3 years5 years10 years
Operating income32.7%24.3%—
Net income33.3%——

Share price return

Finished calendar years

2025202420232022202120202019201820172016
Return-100%3683%4607%1289%225796%15543%4464%23813%3296%1725%

Dividends and splits

Per share, in the currency the company pays

Paid for 0 years.

  • 300-to-1 reverse split · 18 Sept 2015
  • 1000-to-1 reverse split · 20 Nov 2012
  • 100-to-1 reverse split · 18 Apr 2008
  • 100-to-1 reverse split · 31 May 2006

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.